Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Beljanski

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 22, 2013
BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysisSara Samuel, Vladimir Beljanski, Julien Van Grevenynghe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 22, 2017
Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral ImmunityDavid Olagnier, Rassin R Lababidi, Samar Bel Hadj, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 22, 2013
BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysisSara Samuel, Vladimir Beljanski, Julien Van Grevenynghe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 22, 2017
Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral ImmunityDavid Olagnier, Rassin R Lababidi, Samar Bel Hadj, et al.
Pageof 4